$13.96
+0.56 (+4.18%)
Open$13.50
Previous Close$13.40
Day High$14.32
Day Low$13.50
52W High$21.52
52W Low$15.95
Volume—
Avg Volume758.6K
Market Cap126.29M
P/E Ratio26.01
EPS$0.77
SectorBiotechnology
Analyst Ratings
Buy
9 analysts
Price Target
+84.3% upside
Current
$13.96
$13.96
Target
$25.73
$25.73
$18.91
$25.73 avg
$33.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 48.20M | 47.44M | 44.02M |
| Net Income | 4.12M | 5.52M | 4.21M |
| Profit Margin | 8.6% | 11.6% | 9.6% |
| EBITDA | 8.55M | 8.75M | 8.39M |
| Free Cash Flow | 5.08M | 3.59M | 3.32M |
| Rev Growth | -6.7% | +12.6% | +20.6% |
| Debt/Equity | 0.48 | 0.48 | 0.52 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |